SCHEMBL14865613

SCHEMBL14865613

CC(C)(C#N)c1cc(-c2cncc(-c3cc(-c4ccc(CNC5COC5)cc4)no3)n2)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD1 Q15139 5/20 0.43
ATR Q13535 6/20 0.40
ATM Q13315 3/20 0.40
PRKD3 O94806 1/20 0.38
PRKD2 Q9BZL6 1/20 0.38
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
PRKDC P78527 2/20 0.35
JAK2 O60674 1/20 0.35
ABL1 P00519 1/20 0.35
KIT P10721 1/20 0.35
SERPINA2 P20848 1/20 0.35
PIK3R1 P27986 1/20 0.35
FLT4 P35916 1/20 0.35
FLT3 P36888 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
SYK P43405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14865735 0.94 PRKD1 (0.48) PRKD1ATRATMPRKD3PRKD2
SCHEMBL14865823 0.94 PRKD1 (0.48) PRKD1ATRATMPRKD3PRKD2
SCHEMBL14865636 0.94 PRKD1 (0.46) PRKD1ATRATMPRKD3PRKD2
SCHEMBL14865718 0.92 PRKD1 (0.43) PRKD1ATRATMPRKD3PRKD2
SCHEMBL14865695 0.92 PRKD1 (0.52) PRKD1ATRATMPRKD3PRKD2
SCHEMBL14865762 0.89 PRKD1 (0.37) PRKD1ATRATMPRKD3PRKD2
SCHEMBL14865627 0.88 ATR (0.45) PRKD1ATRATMCYP3A4CYP1A2
SCHEMBL12988151 0.88 ATR (0.55) PRKD1ATRATMPRKDCJAK2
SCHEMBL14865681 0.85 CYP3A4 (0.37) PRKD1ATRATMCYP3A4CYP1A2
SCHEMBL14865770 0.82 S1PR1 (0.39) PRKD1ATRATMCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877759-B2 Aminopyrazines as ATR kinase inhibitors Vertex Pharnaceuticals Incorporated (US) 2014-11-04 US disclosed
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 PRKD1 89/4885ATR 1/4885ATM 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.